Given the higher risk and toxicity with surgery and chemotherapy in patients of advanced age, understanding the prevalence of targetable and/or prognostic genomic markers, such as KRAS, NRAS and BRAF p.V600E mutations and MMR deficiency is critical to guide management (12, 13). Here, KRAS is linked to hyperinsulinemic hypoglycemia, familial, 4.